

**Agenda:** To review and evaluate grant applications

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Conference Room: Grand Hall, 5601 Fishers Lane, MD 20852 (Hybrid Meeting).

**Contact Person:** Kelly Y. Poe, Ph.D., Acting Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892–9834, 301–496–7291, [poeky@mail.nih.gov](mailto:poeky@mail.nih.gov).

**Name of Committee:** National Advisory Allergy and Infectious Diseases Council Acquired Immunodeficiency Syndrome Subcommittee.

**Date:** September 11, 2023.

**Closed:** 8:30 a.m. to 10:15 a.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Conference Room: Terrace Room, 5601 Fishers Lane, Rockville, MD 20852 (Hybrid Meeting).

**Open:** 1:00 p.m. to 4:00 p.m.

**Agenda:** Report of the Division Director and Division Staff.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Conference Room: Grand Hall, 5601 Fishers Lane, Rockville, MD 20852 (Hybrid Meeting).

**Contact Person:** Kelly Y. Poe, Ph.D., Acting Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892–9834, 301–496–7291, [poeky@mail.nih.gov](mailto:poeky@mail.nih.gov).

**Name of Committee:** National Advisory Allergy and Infectious Diseases Council Microbiology and Infectious Diseases Subcommittee.

**Date:** September 11, 2023.

**Closed:** 8:30 a.m. to 10:15 a.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Conference Room: Garden 2, 5601 Fishers Lane, Rockville, MD 20852 (Hybrid Meeting).

**Open:** 1:00 p.m. to 4:00 p.m.

**Agenda:** Report of the Division Director and Division Staff.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Conference Room: Garden 2, 5601 Fishers Lane, Rockville, MD 20852 (Hybrid Meeting).

**Contact Person:** Kelly Y. Poe, Ph.D., Acting Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD, 20892–9834, 301–496–7291, [poeky@mail.nih.gov](mailto:poeky@mail.nih.gov).

**Name of Committee:** National Advisory Allergy and Infectious Diseases Council Immunology and Transplantation Subcommittee.

**Date:** September 11, 2023.

**Closed:** 8:30 a.m. to 10:15 a.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Conference Room: Garden 1, 5601 Fishers Lane, Rockville, MD 20852.

**Open:** 1:00 p.m. to 4:00 p.m.

**Agenda:** Report of the Division Director and Division Staff.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Conference Room: Garden 1, 5601 Fishers Lane, Rockville, MD 20852 (Hybrid Meeting).

**Contact Person:** Kelly Y. Poe, Ph.D., Acting Director Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892–9834 301–496–7291, [poeky@mail.nih.gov](mailto:poeky@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://www.nih.gov/about-nih/visitor-information/campus-access-security> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <https://www.niaid.nih.gov/about/advisory-council>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

**Dated:** August 9, 2023.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023–17398 Filed 8–11–23; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; Imaging Technology Development Study Section.

**Date:** August 25, 2023.

**Time:** 2:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

**Contact Person:** Guo Feng Xu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5122, MSC 7854, Bethesda, MD 20892, 301–237–9870, [xuguofen@csr.nih.gov](mailto:xuguofen@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

**Dated:** August 8, 2023.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023–17316 Filed 8–11–23; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Request for Letters of Interest (LOI) for NCI-ComboMATCH Laboratories

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute (NCI) through its National Clinical Trials Network (NCTN) has developed a successor precision medicine trial to 'NCI-Molecular Analysis for Therapy Choice (NCI-MATCH)' entitled 'NCI-ComboMATCH'. The principle of this initiative is to overcome drug resistance to single-agent therapy by developing genomically-directed targeted agent combinations. All combinations must be supported by robust, preclinical *in vivo* evidence.